Pacific Shuanglin Bio pharmacy Co Ltd (000403) - Total Liabilities
Based on the latest financial reports, Pacific Shuanglin Bio pharmacy Co Ltd (000403) has total liabilities worth CN¥1.55 Billion CNY (≈ $226.38 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 000403 cash flow conversion to assess how effectively this company generates cash.
Pacific Shuanglin Bio pharmacy Co Ltd - Total Liabilities Trend (1993–2024)
This chart illustrates how Pacific Shuanglin Bio pharmacy Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check Pacific Shuanglin Bio pharmacy Co Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Pacific Shuanglin Bio pharmacy Co Ltd Competitors by Total Liabilities
The table below lists competitors of Pacific Shuanglin Bio pharmacy Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sionna Therapeutics, Inc. Common Stock
NASDAQ:SION
|
USA | $19.12 Million |
|
Zhejiang CONBA Pharmaceutical Co Ltd
SHG:600572
|
China | CN¥2.97 Billion |
|
Dis-Chem Pharmacies
JSE:DCP
|
South Africa | ZAC13.72 Billion |
|
Medicover AB (publ)
ST:MCOV-B
|
Sweden | Skr20.09 Billion |
|
TX Group AG
SW:TXGN
|
Switzerland | CHF797.00 Million |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
|
USA | $436.36 Million |
|
Guangdong Yizumi Precision Machinery Co Ltd
SHE:300415
|
China | CN¥5.01 Billion |
Liability Composition Analysis (1993–2024)
This chart breaks down Pacific Shuanglin Bio pharmacy Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Pacific Shuanglin Bio pharmacy Co Ltd stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pacific Shuanglin Bio pharmacy Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pacific Shuanglin Bio pharmacy Co Ltd (1993–2024)
The table below shows the annual total liabilities of Pacific Shuanglin Bio pharmacy Co Ltd from 1993 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.33 Billion ≈ $194.44 Million |
+9.94% |
| 2023-12-31 | CN¥1.21 Billion ≈ $176.86 Million |
+7.80% |
| 2022-12-31 | CN¥1.12 Billion ≈ $164.07 Million |
+47.51% |
| 2021-12-31 | CN¥760.07 Million ≈ $111.22 Million |
+10.84% |
| 2020-12-31 | CN¥685.71 Million ≈ $100.34 Million |
+45.88% |
| 2019-12-31 | CN¥470.04 Million ≈ $68.78 Million |
-32.67% |
| 2018-12-31 | CN¥698.08 Million ≈ $102.15 Million |
-8.35% |
| 2017-12-31 | CN¥761.70 Million ≈ $111.46 Million |
+9.38% |
| 2016-12-31 | CN¥696.41 Million ≈ $101.91 Million |
-5.87% |
| 2015-12-31 | CN¥739.82 Million ≈ $108.26 Million |
+0.63% |
| 2014-12-31 | CN¥735.16 Million ≈ $107.58 Million |
-12.01% |
| 2013-12-31 | CN¥835.47 Million ≈ $122.26 Million |
+7.08% |
| 2012-12-31 | CN¥780.27 Million ≈ $114.18 Million |
+15.07% |
| 2011-12-31 | CN¥678.06 Million ≈ $99.22 Million |
+4.09% |
| 2010-12-31 | CN¥651.42 Million ≈ $95.32 Million |
-41.53% |
| 2009-12-31 | CN¥1.11 Billion ≈ $163.04 Million |
+7.39% |
| 2008-12-31 | CN¥1.04 Billion ≈ $151.82 Million |
-37.10% |
| 2007-12-31 | CN¥1.65 Billion ≈ $241.38 Million |
-4.79% |
| 2006-12-31 | CN¥1.73 Billion ≈ $253.54 Million |
-12.05% |
| 2005-12-31 | CN¥1.97 Billion ≈ $288.28 Million |
+30.17% |
| 2004-12-31 | CN¥1.51 Billion ≈ $221.47 Million |
+8.05% |
| 2003-12-31 | CN¥1.40 Billion ≈ $204.97 Million |
+82.97% |
| 2002-12-31 | CN¥765.52 Million ≈ $112.02 Million |
+10.81% |
| 2001-12-31 | CN¥690.82 Million ≈ $101.09 Million |
+19.25% |
| 2000-12-31 | CN¥579.29 Million ≈ $84.77 Million |
+20.96% |
| 1999-12-31 | CN¥478.92 Million ≈ $70.08 Million |
+66.13% |
| 1998-12-31 | CN¥288.28 Million ≈ $42.18 Million |
+50.00% |
| 1997-12-31 | CN¥192.19 Million ≈ $28.12 Million |
+9.41% |
| 1996-12-31 | CN¥175.67 Million ≈ $25.71 Million |
+30.05% |
| 1995-12-31 | CN¥135.07 Million ≈ $19.77 Million |
+0.79% |
| 1994-12-31 | CN¥134.01 Million ≈ $19.61 Million |
-0.48% |
| 1993-12-31 | CN¥134.65 Million ≈ $19.70 Million |
-- |
About Pacific Shuanglin Bio pharmacy Co Ltd
Pacific Shuanglin Bio-pharmacy Co., Ltd., together with its subsidiaries, engages in research, development, production, and sales of blood products in China and internationally. The company offers human serum albumin, intravenous human immunoglobulin (PH4), human immunoglobulin, hepatitis B human immunoglobulin, tetanus and anti-tetanus human immunoglobulin, rabies patient immunoglobulin, human c… Read more